G-NiiB Oral Microbiome Immunity Formula SIM01 Alleviates Post-COVID-19 Conditions Clinical Study Published in the Prestigious International Medical Journal The Lancet Infectious Diseases
We are proud to announce that a ground-breaking large-scale randomised, double-blind, placebo-controlled clinical trial conducted on the efficacy of SIM01, an oral microbiome immunity formula developed by a top-notch medical school in Hong Kong, involving 463 patients who had contracted COVID-19, has strongly proved that the consumption of SIM01, an oral microencapsulated live bacteria formula, could significantly improve the gut microbiota after six months and lead to remarkable alleviation of post-COVID-19 conditions (“long COVID”), encompassing a range of symptoms affecting different systems and organs. The findings of the Trial were published yesterday, 7 Dec, in The Lancet Infectious Diseases, the most authoritative international medical journal in infectious diseases.
Ms. Rachel Fan, CEO of G-NiiB GenieBiome, stated, “The publication of the Trial on G-NiiB’s microbiome immunity formula, SIM01, in the medical journal The Lancet Infectious Diseases, is undoubtedly a scientific feat and a significant milestone for G-NiiB GenieBiome. It represents a great recognition of the leadership, judgment, and expertise of our founder and Chief Scientific Advisor, showcasing our leading position and innovative capabilities in microbiome research. It also serves as a strong testimony of our professional competence and product quality, demonstrating that our core technology has received authoritative approbation from the international medical community. This is considerable progress and an outstanding achievement for a pioneering company to keep a foothold in the microbiome arena. We are immensely proud.”
Published Paper: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00685-0/fulltext
https://doi.org/10.1016/S1473-3099(23)00685-0
CUHK Medicine
Microbiota I-Center (MagIC) (香港微生物菌群創新中心)
GenieBiome Limited 精進微生物科技有限公司
